AER005

N/A

Report date: 2023/10/20 14:37:33

Base Information

Drug NameAER005
Drug Alias NameAER005AER-005
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionSARS-CoV-2 Spike glycoprotein receptor binding domain modulators
TargetsSARS-CoV-2 Spike glycoprotein receptor binding domain
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAerium Therapeutics IncFred Hutchinson Cancer Research Center
China Registration ClassN/A

Develop Information

Active CompaniesAerium Therapeutics IncFred Hutchinson Cancer Research Center
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A